MHRA Alerts Over GLP-1 Medications After Two Fatal Cases and 500 Adverse Reports

Two deaths have been reported in Northern Ireland, with potential links to weight-loss injections approved for use on the NHS. These cases are part of a larger number of suspected adverse drug reactions involving GLP-1 medications, which are widely used for obesity treatment.

The Medicines and Healthcare products Regulatory Agency (MHRA) has recorded over 500 such reports, indicating that the issue is not isolated. In the two fatal cases, one individual had taken Mounjaro, a medication nicknamed the 'King Kong' of fat-busting jabs, while the other involved an unidentified semaglutide-based product. Both medications are part of a class of drugs that include Wegovy, Ozempic, and Rybelsus, which are also used for treating type 2 diabetes.

The MHRA emphasized that a suspected adverse reaction does not confirm that a medicine is responsible. It stated that other illnesses or coincidences could also be to blame. The reports showed that the deceased were a man and a woman, aged in their 40s and 60s, respectively.

Earlier this year, the MHRA issued a warning regarding the potential risk of severe inflammation of the pancreas, a condition that can be life-threatening and is often associated with gallstones. This is a known side effect of the jabs, highlighting the potential dangers these medications may pose to users.

The MHRA has not determined the source of the medication involved in the deaths, leaving open the possibility that the drugs were prescribed, purchased from a pharmacy, or obtained through illegal means. The regulatory body has updated the product information for GLP-1s to highlight the 'small risk of severe acute pancreatitis'.

Symptoms of pancreatitis include severe abdominal pain that radiates to the back and does not subside. Immediate medical attention is advised for anyone experiencing these symptoms. The MHRA is urging users to report any serious adverse effects through the Yellow Card scheme to help mitigate potential risks.

In Northern Ireland alone, over 511 reports have been made in the last two years, with 242 classified as serious. UK-wide figures are believed to be even higher, with approximately 2 million individuals using the jabs, many of whom purchase them privately.

Since their introduction, the MHRA has received over 1,296 Yellow Card reports linking pancreatitis to these drugs. Further concerns have emerged regarding other side effects and potential fatalities associated with the use of GLP-1 medications.

Health officials acknowledge that while the jabs have transformed obesity treatment, they are not a solution without risks. Common side effects include gastrointestinal issues such as nausea, constipation, and diarrhea.

A recent study from the University of Cambridge raised concerns that users may end up in worse health if they regain weight after stopping the treatment. On average, users regain 60% of the weight they lose within a year of discontinuation. If the regained weight is predominantly fat, it could increase the risk of type 2 diabetes and heart disease.

Another study identified twenty individual health problems linked to the use of weight-loss jabs, ranging from mild fainting episodes to more serious concerns such as kidney stones and arthritis. These findings underscore the complexity of the health impacts associated with these medications.

The MHRA continues to monitor the situation closely, urging users to remain vigilant and report any adverse effects. As the use of these drugs expands, the balance between their benefits and risks remains a critical concern for both regulators and the public.